

III Drug R&D Paris

October 26-27, 2026

<https://d-rnd.com/paris/>



TENTATIVE AGENDA

Venue:

**Millennium Hotel Paris
Charles de Gaulle
2 Allée Du Verger Roissy
En France 95700
Paris, France**

KEYNOTE SPEAKERS



Hans-Jorg Schneider

Professor, Saarland University, Germany

Hans-Jorg Schneider has been professor there since 1972, with research spanning reaction mechanisms and NMR spectroscopy to supramolecular chemistry (molecular recognition, cyclodextrin/cyclophane chemistry, synthetic enzyme and receptor analogs), and roughly 300 publications.



David J. Greenblatt

Professor, Tufts University, Boston, MA

David J. Greenblatt has been on the Tufts faculty since 1979. A Harvard Medical School grad, he's spent five decades studying drug interactions and pharmacokinetics — especially in psychopharmacology — with over 1,100 publications, and he's Editor-in-Chief of *Clinical Pharmacology in Drug Development*.



Patrick Neven

Professor, University Hospital Leuven, Belgium

He's a professor and gynaecological oncologist at KU Leuven and University Hospitals Leuven, specializing in breast cancer and senology. He's a principal investigator on numerous breast cancer trials, has published widely on endocrine therapy and CDK4/6 inhibitors, and was elected President of the Flemish Gynaecologic Oncology Group in 2009.



Bilada Bilican

Sr. Director, AstraZeneca, Sweden

Bilada Bilican, PhD, is Senior Director at AstraZeneca's Centre for Genomics Research. With over 15 years' experience, he has advanced target and therapeutic discovery through iPSC technologies, mechanistic biology, and automation

KEYNOTE SPEAKERS



Peter Timmerman

Head-Peptide Science, Biosynth B.V., the Netherlands

Peter Timmerman is the inventor of CLIPS technology (a peptide-cyclization platform for constrained peptide drug discovery) and has led peptide science at Biosynth since 2001, originally as CSO of Pepscan before its 2022 acquisition. He also held a professorship in Protein Mimetic Chemistry at the University of Amsterdam from 2007–2022.



Victoire de Margerie

Founder & CEO, Rondol Industrie, France

Victoire de Margerie founded Rondol Industrie in 2012 to bring hot-melt extrusion technology to micro-scale, pharmaceutical-grade manufacturing, building on 35 years in the materials industry across several countries. She also sits on the boards of Boliden, Ivanhoe Electric, and Verkor, and is an elected member of the National Academy of Technologies of France.



Russel J. Reiter

Professor, UTHSC, San Antonio, TX

Russel J Reiter is a Professor of Cell Systems and Anatomy at UT Health San Antonio, known for over six decades of research on melatonin — its actions in humans, animals, and plants, and its roles in oxidative stress and aging. He's Editor-in-Chief of *Melatonin Research*, a Clarivate Highly Cited Researcher, and holds several honorary doctorates.



Sangwook Wu

CEO & CTO, PharmCADD, South Korea

Sangwook Wu co-founded and leads PharmCADD, an AI and physics-driven drug discovery company built around the Pharmulator platform (protein structure prediction, molecular dynamics, quantum calculation, and AI drug generation). PharmCADD has advanced pipelines including Korea's first COVID-19 mRNA vaccine candidate to reach clinical trials.

SESSIONS

Drug Discovery

- High Throughput Screening
- Hit and Lead Identification Assay
- Development Lead Generation and Optimization
- In Vivo and In Vitro Assays
- Screening Compound Libraries
- Synthetic Organic Chemistry
- Computational Chemistry

Drug Design & Development

- Lead Optimization
- Drug Development from an Optimized Lead
- Structure based Drug Designing
- Case Studies of Successful Drugs
- Pre-Clinical & Clinical Research
- Artificial Intelligence
- Pharmacophore & Virtual Screening
- ADME Characterization

Drug Chemistry

- Ubiquitin-Induced Protein Degradation
- Fragment-Based Drug Discovery
- Kinase Inhibitor Chemistry
- Macrocyclics & Constrained Peptides
- Protein-Protein Interactions
- Small Molecules
- Encoded Libraries
- Drug Metabolism

Drug Targets & Therapy

- Target Identification and Validation
- Quantitation of Drug Effects
- Molecular Drug Targets
- Cell Signalling Modalities
- Pharmacotherapy
- PKPD
- Drug-Target Interactions
- RNA as a Small Molecule Target

SESSION SPEAKERS



Amin Li

Vice President-Medicinal Chemistry, Jacobio Pharma, China

Title to be Updated



Bruce Seligmann

CSO, BioSpyder Technologies, Inc., Carlsbad, CA

High-Throughput Transcriptomics: From Animal-Free Safety Assessment to NextGen Drug Discovery with Functional Signature Targeting and Lead Optimization



Shiva Sharareh

Founder & CEO, Rekovar Inc, Irvine, CA

Title to be Updated



Mehdi Ashraf-Khorasani

Sr. Research Scientist, Virginia Tech, Blacksburg, VA

Qualitative and Quantitative Analyses of the Enantiomers of Nicotine and Nornicotine Employing Chiral Supercritical Fluid Chromatography



Chris Adams

CEO, Diopter Technologies, Somerville, MA

Drug delivery via advanced contact lenses and dissolvable amniotic membrane biopolymer devices for ocular surface injuries and post-surgical recovery



Shadi Hamoud

Deputy Director, Rambam Health Care Campus, Israel

Title to be Updated



Joseph T Jr Nickels

Director, Institute of Metabolic Disorders, Trenton, NJ

Targeting Monoacylglycerol Acyltransferase 2 for Treating Obesity



William E. Roudebush

Clinical Professor, University of South Carolina, Greenville, SC

Overcoming Infertility: Platelet-Activating Factor as a Therapeutic Catalyst in Reproduction



Karim Khaled

Assistant Professor, Lebanese American University, Lebanon

A Structural Equation Modeling Approach to Examine the Mediating Effect of Stress on Diet in Culturally Diverse Women of Childbearing Age



Cristina Scavone

Associate Professor, University of Campania "Luigi Vanvitelli", Italy

Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database

**Lin Wang**

Co-Founder, CEO & President, Ascent Bio-Nano Technologies Inc., Morrisville, NC

Precision at the 10 μ l Scale: Replacing the Centrifuge with Automated Acoustofluidics for High-Yield Drug R&D

**Laszlo Fusti-Molnar**


Founder, QuantumFuture Scientific Software LLC Buda, TX

Fighting Cancer and Alzheimer's Disease: QuantumFuture's Docking (QFD) Identifies Dozens of Potent, Safe IDO1 Inhibitors from Natural Products

**Massimo Zollo**

Professor, University of Naples Federico II, Italy

Title to be Updated

**Despoina Pantazi**

Chemist, University of Ioannina, Greece

Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies

**Georg Voelcker**

Research Associate, Goethe University Frankfurt, Germany

Apoptosis Activation in Tumor Cells Using Novel Cyclophosphamides

**Tony Jun Huang**

William Bevan Distinguished Professor, Duke University, Durham, NC

Precision at the 10 μ l Scale: Replacing the Centrifuge with Automated Acoustofluidics for High-Yield Drug R&D



Rana Rais

Associate Professor, The Johns Hopkins University Baltimore, MD


Brain delivery of nSMase2 inhibitor using prodrug approaches and dendrimer nanoparticle systems



Shengqiang Li

Founder & CSO, Sciogen LLC, Gaithersburg, MD

Novel G protein-based RSV vaccine



Luke Lairson

Professor, The Scripps Research Institute, La Jolla, CA


Regenerative medicine for the treatment of MS: Enhancing repair to prevent progression



Pierre Bernard-Savary

Founder, Chromacim sas, France

High-performance thin-layer chromatography now in France—recent developments of the Club de CCM and perspectives



Brian S. J. Blagg

Charles Huisling Professor, University of Notre Dame, Notre Dame, IN

Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer



Raúl Loera-Valencia

Principal Investigator, Tecnológico de Monterrey, Mexico

Title to be Updated



Wasif M Saif

Professor, Karmanos Cancer Institute, Detroit, MI

Title to be Updated



Adisa Trnjanin

Co-Founder, C2D2, Switzerland

Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis



Yohannes Hagos

CEO, PortaCellTec Biosciences GmbH, Germany

Functional characterization and comparison of human and mouse organic anion transporter 1 as drugs and pesticides uptake carrier



Ahmed Abdelhakeem

Clinical Fellow, Mayo Clinic, Jacksonville, FL

Title to be Updated



João Paulo-Fernandes

Workers Committee, INFARMED, I.P., Portugal

Title to be Updated



Michel De Waard

Senior Research Director, Inserm, France

Drug design based on natural peptides



Anita Wegert

Director, Med Chem, Symeres, the Netherlands


Title to be Updated



Khadijeh Esmaeilpour

Neuroscientist, University of Toronto, Canada

Boosting decision-making in rat models of early-life adversity with environmental enrichment and intranasal oxytocin



Gregory Lavieu

Chaire d'Excellence, Université Paris Cité, France

Exosome-based vectors for targeted drug delivery



Vetriselvan Subramaniyan

Professor, Sunway University, Malaysia

Targeted Therapeutics in Obesity: Integrating Radiological and Molecular Phenotyping



Mohammad A. Altamimi

Professor | Vice Dean, King Saud University, Saudi Arabia

Title to be Updated



Amer Mahmood

Associate Professor, King Saud University, Saudi Arabia

Title to be Updated



Zhude Tu

Professor, Washington University, St. Louis, MO

Title to be Updated



Phelelisiwe Dube

Post Doctoral Fellow, North-West University, South Africa

Novel, Achiral 4-Nitroimidazole Compounds with Potent Antitubercular Activity



Victoria Freund

Research Group Head, Fresenius University of Applied Sciences, Germany

Beyond AI Hype: Understanding Innovation Diffusion in Pharmaceutical R&D



Ryan Logan

Professor, UMass Chan Medical School, Worcester, MA

Circadian rhythm disruptions associated with opioid use disorder in synaptic proteomes of human dorsolateral prefrontal cortex and nucleus accumbens



Md. Jashim Uddin

Associate Professor, Vanderbilt University, Nashville, TN

Discovery of COX-2-Targeted Nanobodies for Optical Imaging of Colorectal Adenomas



Subhash Chauhan

Professor, The University of Texas Rio Grande Valley, McAllen, TX

Novel Therapeutic Strategies for Pancreatic Cancer



Abdelazim Zaghloul

Associate Professor, Kuwait University, Kuwait

Famotidine/Diclofenac Sodium Novel Gastroretentive Bilayer Tablet Dosage Form: Formulation, Characterization and Optimization Studies



Richard B. Meagher

Professor, University of Georgia, Athens, GA

Title to be Updated



Romi Gupta

Associate Professor, The University of Alabama at Birmingham, Birmingham, AL


Title to be Updated



Amit Sachdeva

Associate Professor, University of East Anglia, UK

Towards development of light-responsive antibody fragments for next-generation biotherapeutics



Hideaki Yano

Assistant Professor, Northeastern University, Boston, MA

Title to be Updated

**Oliver Zerbe**

Professor, University of Zurich, Switzerland

Macrocyclic peptides as disrupters of protein-protein interactions and antibiotics against multi-resistant Gram-negative bacteria

Presentation Slots are Available